Kousai Bio Co., Ltd.
5 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| A Phase I Clinical Study of KSD-101 in Patients With Relapsed or Refractory EBV-associated Hematological Malignancies (NCT07532746) | Kousai Bio Co., Ltd. | 2026-05-01 |
| KSD-201 Treatment for Advanced Clear Cell Renal Cell Carcinoma: an Early Exploratory Clinical Study (NCT06708936) | Kousai Bio Co., Ltd. | 2026-03-01 |
| KSD-101 Therapy for Standard Treatment Failed EBV-associated Nasopharyngeal Carcinoma: an Exploratory Clinical Trial (NCT06752473) | Kousai Bio Co., Ltd. | 2025-01-31 |
| KSD-101 Therapy for EBV-associated Nasopharyngeal Carcinoma: an Exploratory Clinical Trial (NCT06097793) | Kousai Bio Co., Ltd. | 2023-12-04 |
| KSD-101 Therapy for EBV-associated Lymphomas: an Exploratory Clinical Trial (NCT05882305) | Kousai Bio Co., Ltd. | 2023-06-10 |
Track Kousai Bio Co., Ltd. automatically
Every clearance here is in the API, with alerts when new ones post.